Back to Agenda
Global Regulatory Harmonization for Increased Patient Access to Medicines Through the International Council for Harmonisation (ICH)
Session Chair(s)
Amanda Roache, MS
Deputy Vice President, Science and Regulatory Advocacy , PhRMA, United States
Leaders in global pharmaceutical development and regulation will convene to share views on the latest advancements under ICH, including new areas of work, and to discuss areas of emerging importance and ICH’s thinking around a multi-year strategy. There will also be discussion of the role of ICH guidelines during the COVID-19 pandemic and any related learnings for regulatory science and possible future ICH harmonization.
Learning Objective : Discuss progress in the harmonization of regional requirements for the development and manufacture of pharmaceuticals; Describe ICH’s multi-year strategy and areas that will be important for global alignment in the years to come; Identify ICH’s role in responding to the global pandemic and any opportunities for learnings to be addressed in ICH guidelines.
Speaker(s)
Theresa Mullin, PHD
Associate Center Director - CDER, FDA, United States
ICH Multiyear Strategy and Future Vision
Si Yuan Zhou
Director of CDE, Head of ICH China Office, National Medical Products Adminsitration (NMPA), China
NMPA Perspective on ICH Progress and Future Approach
Gustavo Mendes Lima Santos, MPHARM
Herbal and Complementary Medicines Office - GMESP, Brazilian Health Regulatory Agency (ANVISA), Brazil
ANVISA Perspective on ICH and Recent Advancements in Brazil
Sharon Olmstead
Global Head, Regulatory & Development Policy, Novartis Pharmaceuticals Corporation, United States
IFPMA’s Role in ICH and Future Outlook
Have an account?